Kondoh, Yasuhiro
Suda, Takafumi
Hongo, Yoshie
Yoshida, Manami
Hiroi, Shinzo
Iwasaki, Kosuke
Takeshima, Tomomi
Homma, Sakae
Funding for this research was provided by:
Shionogi
Article History
Received: 28 September 2021
Accepted: 22 January 2022
First Online: 8 February 2022
Declarations
:
: Ethical approval and consent were not required according to Ethical Guidelines Medical and Health Research Involving Human Subjects by the Ministry of Education, Culture, Sports, Science and Technology, and the Ministry of Health, Labour and Welfare, Japan, because the data used in this study had been anonymized.
: Not applicable.
: Yasuhiro Kondoh has received lecture fees from Nippon Boehringer Ingelheim Co., Ltd., and Shionogi Co., Ltd. Takafumi Suda has received lecture fees from Nippon Boehringer Ingelheim Co., Ltd. and AstraZeneca K.K., and received research funding from Nippon Boehringer Ingelheim Co., Ltd., Novartis Pharma K.K., Ono Pharmaceutical Co., Ltd., and AstraZeneca K.K. He also received subsidies or donations from Astellas Pharma Inc., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Company Limited, Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Novartis Pharma K.K., Pfizer Japan Inc., and Nippon Boehringer Ingelheim Co Ltd. Yoshie Hongo, Manami Yoshida, and Shinzo Hiroi are employees of Shionogi & Co., Ltd., and own shares in Shionogi & Co., Ltd. Kosuke Iwasaki and Tomomi Takeshima are employees of Milliman Inc., which has received consultancy fees from Shionogi & Co., Ltd. Sakae Homma has received lecture fees from Nippon Boehringer Ingelheim Co., Ltd. He belongs to an endowed department sponsored by Nippon Boehringer Ingelheim Co., Ltd., Shionogi & Co., Ltd., and Chugai Pharmaceutical Co., Ltd.